ADC Therapeutics (ADCT) Receivables - Net (2021 - 2026)

ADC Therapeutics has disclosed Receivables - Net across 6 years of filings, most recently posting $28.0 million for Q2 2026.

• In Q2 2026, Receivables - Net rose 7.07% year-over-year to $28.0 million; the TTM figure through Jun 2026 stood at $28.0 million (up 7.07% YoY), while the FY2025 annual figure was $29.1 million, up 43.32% from the prior year.
• Receivables - Net came in at $28.0 million for Q2 2026 at ADC Therapeutics, down from $31.0 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $73.0 million in Q4 2022 to a low of $20.3 million in Q4 2024.
• Average Receivables - Net over 5 years is $27.6 million, with a median of $24.0 million recorded in 2023.
• Year-over-year, Receivables - Net jumped 903.51% in 2022 and sank 65.49% in 2023.
• Over 5 years, Receivables - Net stood at $73.0 million in 2022, then slumped by 65.49% to $25.2 million in 2023, then dropped by 19.32% to $20.3 million in 2024, then surged by 43.32% to $29.1 million in 2025, then retreated by 3.72% to $28.0 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $28.0 million in Q2 2026, $31.0 million in Q1 2026, and $29.1 million in Q4 2025.